Latest Period
n/a
Security Snapshot
Ernexa Therapeutics Inc. - Common Stock (ERNA) Institutional Ownership
CUSIP: 114082209
13F Institutional Holders and Ownership History from Q4 2022 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.18
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ERNA on Nasdaq
- Shares outstanding
- 1,166,181
- SEC-reported price per share
- $0.18
- Insider filing price
- $0.18
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ERNA - Ernexa Therapeutics Inc. - Common Stock is tracked under CUSIP 114082209.
- Latest finished 13F holder period is not available.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 26 to 0 between Q1 2025 and Q2 2025.
- SEC-reported value moved from $264,200 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
114082209
Latest holder period
n/a
13F holders
13D/G owners
7
CIK / CUSIP context first
ERNA full holder history
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Ernexa Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 114082209:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ERNA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cherington Charles | 38% | +15% | $8,755,063 | +$4,464,210 | 41,690,775 | +104% | Charles Cherington | 09 Jun 2025 |
| Freebird Partners LP | 9.9% | -0.9% | $1,304,421 | +$225,715 | 6,211,530 | +21% | Freebird Partners LP | 31 Mar 2025 |
| HALPERN JOHN D | 9.6% | -3.9% | $1,254,084 | +$175,402 | 5,971,830 | +16% | John D. Halpern | 31 Mar 2025 |
| IAF, LLC | 5.2% | -0.4% | $683,638 | +$121,003 | 3,255,421 | +22% | IAF, LLC | 31 Mar 2025 |
| Singer Nicholas Jason | 4.9% | $538,650 | 2,565,001 | Nicholas Jason Singer | 31 Dec 2024 | |||
| Konar Shameek | 9.7% | +84% | $21,302 | -$597,053 | 118,342 | -97% | Shameek Konar | 10 Feb 2026 |
| Bleichroeder LP | 6.9% | $14,400 | 80,000 | Bleichroeder LP | 31 Mar 2026 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
n/a
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 0 | $0 | -$264,175 | $0.18 | 0 |
| 2025 Q1 | 1,488,385 | $264,200 | +$76,046 | $0.18 | 26 |
| 2024 Q4 | 994,393 | $292,358 | +$69,713 | $0.29 | 24 |
| 2024 Q3 | 711,299 | $746,882 | +$337,331 | $1.05 | 20 |
| 2024 Q2 | 390,079 | $712,390 | -$47,643 | $1.83 | 19 |
| 2024 Q1 | 409,206 | $982,076 | +$130,770 | $2.40 | 22 |
| 2023 Q4 | 355,004 | $636,892 | +$42,245 | $1.80 | 19 |
| 2023 Q3 | 331,449 | $728,429 | -$4,855 | $2.18 | 20 |
| 2023 Q2 | 333,250 | $750,186 | -$15,587 | $2.26 | 19 |
| 2023 Q1 | 331,798 | $1,135,164 | +$6,895 | $3.40 | 19 |
| 2022 Q4 | 329,815 | $1,192,085 | +$995,056 | $3.22 | 18 |